Evidence map›Paper›PMID 34917382›Full record

ArticleClinical case reports2021

Leukocyte chemotactic factor 2-related amyloidosis presenting with severe jaundice and hepatic encephalopathy.

Hussam Almasri, Almurtada Razok, Ahmed Badi, Muneera Almohannadi, Abdo Lutf, Mahir Petkar, Abdelnaser Elzouki

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hussam AlmasriDepartment of Medicine Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0000-0002-9549-8352
Almurtada RazokDepartment of Medicine Hamad Medical Corporation Doha Qatar.
Ahmed BadiDepartment of gastroenterology and hepatology Hamad Medical Corporation Doha Qatar.
Muneera AlmohannadiDepartment of gastroenterology and hepatology Hamad Medical Corporation Doha Qatar.
Abdo LutfDepartment of Medicine Hamad Medical Corporation Doha Qatar.
Mahir PetkarDepartment of Pathology Hamad Medical Corporation Doha Qatar.
Abdelnaser ElzoukiDepartment of Medicine Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0000-0002-9132-1752
Hamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis is a well-known disease with various types and subtypes. One of the most recently identified types is leukocyte chemotactic factor 2 amyloidosis (LECT 2), which was found to be common in certain ethnic backgrounds. It is suggested that the diagnosis of this type is vital to prevent any therapy-related complications when it is erroneously diagnosed as AL amyloidosis. The clinical presentation is usually slowly progressive kidney disease and mild hepatic impairment. We report a case of LECT2 amyloidosis, which presented with severe painless cholestasis and hepatic encephalopathy alongside progressive kidney disease.

Indexed as

cholestasisend‐stage renal diseaseLeukocyte chemotactic factor 2 amyloidosis

Identifiers

PMID34917382
PMCPMC8645169
OpenAlexW4200190946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.